Literature DB >> 24939758

Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors.

Ming-Fu Cheng1, Ming-Shiu Hung1, Jen-Shin Song1, Shu-Yu Lin1, Fang-Yu Liao1, Mine-Hsine Wu1, Wenchi Hsiao1, Chia-Ling Hsieh1, Jian-Sung Wu1, Yu-Sheng Chao1, Chuan Shih1, Su-Ying Wu2, Shau-Hua Ueng3.   

Abstract

A novel class of phenyl benzenesulfonylhydrazides has been identified as potent inhibitors of indoleamine 2,3-dioxygenase (IDO), and their structure-activity relationship was explored. Coupling reactions between various benzenesulfonyl chlorides and phenylhydrazides were utilized to synthesize the sulfonylhydrazides bearing various substituents. Compound 3i exhibited 61 nM of IC50 in enzymatic assay and 172 nM of EC50 in the HeLa cell. The computational study of 3i suggested that the major interactions between 3i and IDO protein are the coordination of sulfone and heme iron, the hydrogen bonding and hydrophobic interactions between 3i and IDO. This novel class of IDO inhibitor provides a new direction to discover effective anti-cancer agents.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Indoleamine 2,3-dioxygenase; Molecular docking; Structure–activity relationship; Sulfonylhydrazide

Mesh:

Substances:

Year:  2014        PMID: 24939758     DOI: 10.1016/j.bmcl.2014.05.084

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  8 in total

1.  O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1.

Authors:  William P Malachowski; Maria Winters; James B DuHadaway; Ariel Lewis-Ballester; Shorouk Badir; Jenny Wai; Maisha Rahman; Eesha Sheikh; Judith M LaLonde; Syun-Ru Yeh; George C Prendergast; Alexander J Muller
Journal:  Eur J Med Chem       Date:  2015-12-17       Impact factor: 6.514

Review 2.  Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.

Authors:  Xiu-Xiu Wang; Si-Yu Sun; Qing-Qing Dong; Xiao-Xiang Wu; Wei Tang; Ya-Qun Xing
Journal:  Medchemcomm       Date:  2019-08-15       Impact factor: 3.597

3.  Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors.

Authors:  Kun Fang; Guoqiang Dong; Yu Li; Shipeng He; Ying Wu; Shanchao Wu; Wei Wang; Chunquan Sheng
Journal:  ACS Med Chem Lett       Date:  2018-03-26       Impact factor: 4.345

Review 4.  Discovery of IDO1 Inhibitors: From Bench to Bedside.

Authors:  George C Prendergast; William P Malachowski; James B DuHadaway; Alexander J Muller
Journal:  Cancer Res       Date:  2017-12-15       Impact factor: 12.701

Review 5.  Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'.

Authors:  George C Prendergast; Arpita Mondal; Souvik Dey; Lisa D Laury-Kleintop; Alexander J Muller
Journal:  Trends Cancer       Date:  2017-12-21

Review 6.  Advances in indoleamine 2,3-dioxygenase 1 medicinal chemistry.

Authors:  Alice Coletti; Francesco Antonio Greco; Daniela Dolciami; Emidio Camaioni; Roccaldo Sardella; Maria Teresa Pallotta; Claudia Volpi; Ciriana Orabona; Ursula Grohmann; Antonio Macchiarulo
Journal:  Medchemcomm       Date:  2017-05-16       Impact factor: 3.597

7.  Discovery of secondary sulphonamides as IDO1 inhibitors with potent antitumour effects in vivo.

Authors:  Shushan Ge; Haiqing Zhong; Xuewei Ma; Yingbo Zheng; Yi Zou; Fang Wang; Yan Wang; Yue Hu; Yuezhen Li; Wen Liu; Wenjie Guo; Qiang Xu; Yisheng Lai
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

Review 8.  Trial watch: IDO inhibitors in cancer therapy.

Authors:  Julie Le Naour; Lorenzo Galluzzi; Laurence Zitvogel; Guido Kroemer; Erika Vacchelli
Journal:  Oncoimmunology       Date:  2020-06-14       Impact factor: 8.110

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.